E H Jakobsen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

E H Jakobsen

Showing results (1-10 of 2) with videos related to

Pageof 1

Sort By:

Breast (Edinburgh, Scotland)|January 25, 2026

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancerK G Svalheim, N K Andresen, C Bjerre, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyH S Han, V Diéras, M Robson, et al.

Pageof 1

Search research articles

Showing results (1-10 of 2) with videos related to

Sort By:

Pageof 1

Breast (Edinburgh, Scotland)|January 25, 2026

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancerK G Svalheim, N K Andresen, C Bjerre, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyH S Han, V Diéras, M Robson, et al.

Pageof 1